2022 Bladder Cancer Update Bulletin: Key Opinion Leader (KOL) Views on Recent Developments - ResearchAndMarkets.com

2022-11-28
Business Wire
临床2期疫苗免疫疗法临床结果ASCO会议
DUBLIN--(BUSINESS WIRE)--The "Bladder Cancer: Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering.
This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market.
Topics covered include: Bristol-Myers Squibb (BMS) presenting positive data from a Phase I/II study investigating a combination of its PD-1 inhibitor Opdivo (nivolumab) with its pipeline indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, BMS-986205, in heavily pretreated patients with advanced bladder cancer; BioCanCell announcing final results for its Phase IIb combination trial investigating its lead compound BC-819 in combination with the BCG vaccine in 38 patients with intermediate-and high-risk non-muscle invasive bladder cancer (NMIBC); KOLs offering their updated opinions on the the supply status of the BCG vaccine in the US and key European markets.
Business Questions:
How do the KOLs perceive the Phase II combination results for BMS' Opdivo with the IDO inhibitorIDO inhibitor BMS-986205 in patients with advanced bladder cancer?
Do KOLs view PD-1/PD-L1 and IDO inhibition as a viable combination approach going forward?
What are experts' thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer?
Do KOLs hold any other concerns about dual immunotherapy combinations such as cost, access or increased risk of toxicity?
If approved, how and when would KOLs consider using the combination approach of Opdivo with an IDO inhibitorIDO inhibitor?
Based on published Phase II data, how do the experts view the results so far for BC-819 with BCG in patients with NMIBC?
Are the KOLs enthusiastic about intravesical gene therapies as treatments for NMIBC and if so, why?
How do the experts perceive the planned Phase III trial investigating BC-819 in patients that are BCG-recurrent?
If approved, can BC-819 gain market share in patients with high-risk or intermediate-risk NMIBC?
What are KOLs' opinions on the supply shortages previously reported for the BCG vaccine and are they being addressed?
For more information about this newsletter visit https://www.researchandmarkets.com/r/9ke1kl
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。